![]() |
Most major pharmaceutical manufacturers spend an average of 15% of sales on research & development. Given this substantial cost and the long development cycle, companies need to find ways to improve R&D productivity in order to continue to meet the world’s medical needs.
The issues involved in effectively carrying out research & development are complex and transcend science. Organisations must have a solid R&D vision to anticipate regulatory changes, control costs and prepare for the development of the new generation of pharma products.
PwC’s publication Pharma 2020: Virtual R&D provides a visionary perspective on the change drivers that will impact research & development productivity and offer greater opportunities for the development of truly innovative products which provide greater benefit to healthcare payers and providers and greater value for the companies involved.